ERBB2 and breast carcinoma: The phase 3 ExteNET trial, evaluating 1 year of neratinib as extended adjuvant therapy in HER2 + breast cancer, did not mandate the use of anti-diarrheal prophylaxis, instead recommending treatment with anti-diarrheal agents and/or dose modifications after symptom onset.